信迪利单抗联合奥沙利铂+替吉奥化疗方案治疗晚期胃癌的效果及对患者生存率、血清肿瘤标志物水平的影响  

Effect of Sintilimab Combined with Oxaliplatin+Tegafur,Gimeracil and Oteracil Potassium Chemotherapy in the Treatment of Advanced Gastric Cancer and its Effect on Survival Rate and Serum Tumor Marker Level

作　　者：单风晓 胡少博 武阳 SHAN Fengxiao;HU Shaobo;WU Yang(Department of Oncology,Luoyang Central Hospital Afiliated to Zhengzhou University,Luoyang 471000,Henan,China)

机构地区：[1]郑州大学附属洛阳中心医院肿瘤科三病区,河南洛阳471000

出　　处：《中国药物滥用防治杂志》2024年第12期2277-2279,共3页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：河南省医学科技攻关计划项目(编号:LHGJ20220936)。

摘　　要：目的:探讨晚期胃癌患者应用信迪利单抗联合奥沙利铂^(+)替吉奥(SOX)化疗方案对生存率及血清肿瘤标志物水平的影响。方法:随机选取2021年6月—2023年6月我院收治的晚期胃癌患者94例,根据就诊序号采用随机双盲法分为对照组(n=47)、联合组(n=47)。对照组给予常规治疗^(+)SOX化疗方案治疗,联合组基于对照组加用信迪利单抗治疗。比较两组临床疗效、免疫功能指标、肿瘤标志物水平、远期生存率及毒副反应发生率。结果:联合组客观缓解率(ORR)、疾病控制率(DCR)分别为59.57%、89.36%,均高于对照组的38.30%、72.34%(P<0.05);两组治疗后CD3^(+)、CD4^(+)/CD8^(+)、CD4^(+)均下降,但联合组下降幅度小于对照组(P<0.05);联合组治疗后CEA、CA724、CA199、CA125水平低于对照组(P<0.05);联合组半年、1年生存率均高于对照组(P<0.05);两组Ⅰ-Ⅳ级毒副反应发生率比较,差异无统计学差异(P>0.05)。结论:信迪利单抗联合SOX化疗治疗晚期胃癌患者的效果明显,不仅可改善免疫功能、降低肿瘤标志物水平,还可提高生存率,且安全性良好。Objective:To investigate the effect of Sintilimab combined with oxaliplatin^(+)tegafur,gimeracil and oteracil potassium(SOX)chemotherapy on survival rate and serum tumor markers in patients with advanced gastric cancer.Methods:A total of 94 patients with advanced gastric cancer admitted to our hospital from June 2021 to June 2023 were randomly selected and divided into control group(n=47)and combined group(n=47)by random double-blind method according to the number of visits.The control group was treated with conventional treatment^(+)soX chemotherapy,and the combined group was treated with Sintilimab based on the control group.The clinical efficacy,immune function index,tumor marker level,long-term survival rate and incidence of toxic and side effects were compared between the two groups.Results:The objective response rate(ORR)and disease control rate(DCR)in the combined group were 59.57%and 89.36%,respectively,which were higher than 38.30%and 72.34%in the control group(P<0.05).After treatment,CD3^(+),CD4^(+)/CD8^(+)and CD4^(+)in the two groups decreased,but the decrease in the combined group were smaller than those in the control group(P<0.05).After treatment,the levels of CEA,CA724,CA199 and CA125 in the combined group were lower than those in the control group(P<0.05).The half-year and one-year survival rates of the combined group were higher than those of the control group(P<0.05).There was no significant difference in the incidence of grade I-IV toxic and side effects between the two groups(P>0.05).Conclusion:The effect of Sintilimab combined with SOX chemotherapy in the treatment of patients with advanced gastric cancer is obvious,which can not only improve the immune function,reduce the level of tumor markers,but also improve the survival rate,and the safety is good.

关 键 词：胃癌 信迪利单抗 奥沙利铂 替吉奥 生存率 肿瘤标志物 

分 类 号：R73[医药卫生—肿瘤]